HOME >> BIOLOGY >> NEWS
Novel therapeutic bortezomib moves to phase II trial in lung cancer patients

(NEW ORLEANS) -- A three-drug combination including the novel molecularly targeted agent bortezomib, the first drug in its class, proved well-tolerated and showed promising efficacy in patients with advanced non-small cell lung cancer, according to phase I trial results reported Saturday at the annual meeting of the American Society of Clinical Oncologists.

The triple-therapy regimen will now be tested nationally in a phase II trial as first-line therapy for advanced non-small cell lung cancer. Angela Davies, assistant professor of hematology/oncology and principal investigator of the phase I trial, will lead the phase II trial as well.

The regimen consists of bortezomib, gemcitabine and carboplatin. Gemcitabine and carboplatin represent an accepted first-line treatment combination for advanced non-small cell lung cancer.

In the small phase I trial, the three drugs were administered on a similar schedule. Out of 12 patients, four had a partial response and seven had stable disease.

In the larger phase II trial, which will enroll 99 patients, the drugs will be given sequentially, with bortezomib following the chemotherapy drugs. Preclinical research at UC Davis Cancer Center suggests that giving bortezomib last may be more effective than giving it first or at the same time.

Bortezomib is a proteasome inhibitor that blocks the signals cancer cells rely on to degrade cellular proteins. The result is a buildup of proteins that hastens cell death.

Bortezomib has been approved by the Food and Drug Administration for the treatment of multiple myeloma, but had not been tested before in non-small cell lung cancer.

"Bortezomib is an exciting therapeutic, and we're encouraged that we've been able to take this promising three-drug combination immediately from phase I to phase II," Davies said.

Of the estimated 175,000 new cases of lung cancer diagnosed in the United States each year, nearly 80 percent are n
'"/>

Contact: Claudia Morain
530-219-5053
University of California, Davis - Health System
5-Jun-2004


Page: 1 2

Related biology news :

1. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
2. Novel approaches to current cellular therapies continue progress toward disease prevention
3. Novel therapies show promise against myeloid leukemia
4. Novel sensors help clear the air
5. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
6. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
7. Novel therapeutic target identified in fight against Rheumatoid Arthritis
8. Novel bacterium detoxifies chlorinated pollutants
9. Novel flu vaccine shows promise in mice
10. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician
11. Novel method identifies hidden genes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/18/2019)... ... 18, 2019 , ... Early engagement not only improves and ... improves participation by better balancing scientific objectives with patient goals. , Reaching out ... entire process from development to market. Involving these groups in this manner ensures ...
(Date:3/14/2019)... ... ... Highmark Health’s VITAL Innovation Platform has been named the winner in the “Corporate Innovation” ... top honors in the awards. Winners were announced at an event on March 12 ... May 10 that also raises funds for Carnegie Science Center programs that inspire young ...
(Date:3/12/2019)... ... March 12, 2019 , ... FEITIAN Technologies ... all-in-one smart cards, announced today the launch of two new payment card types ... Dynamic CVV Payment cards. These advanced technologies will help all elements of the ...
Breaking Biology News(10 mins):
(Date:3/12/2019)... LIÈGE, Belgium (PRWEB) , ... March 12, 2019 ... ... for sample preparation and epigenetics research, has launched its third generation long-fragment DNA ... the second generation instrument with a user-friendly interface, automated processing, and the ...
(Date:3/5/2019)... ... 2019 , ... San Fransisko, or Sisko for short, is a German warmblood ... to pursue a career in dressage. According to Deborah, dressage came easy to ... ever worked with. Unfortunately, Sisko suffered an injury while playing in his pasture. ...
(Date:2/26/2019)... ... 2019 , ... The idea for Visikol began originally at ... tissue clearing technology for improved tissue characterization. From this initial idea, Visikol emerged ... primarily a services focused company. , Today, Visikol operates as a contract ...
(Date:2/16/2019)... TORONTO (PRWEB) , ... February 14, 2019 , ... ... data visualization, analytics, and knowledge sharing capability that also provides the flexibility for ... and play” functionality. It also provides a shared workbench to conduct quick analytics ...
Breaking Biology Technology:
Cached News: